| ¿µ¹® | prosthetic valve | ÇÑ±Û | ÀΰøÆÇ¸· |
|---|---|---|---|
| ¼³¸í | ½ÉÀå ³»ºÎÀÇ ÀΰøÆÇ¸·. ½ÉÀåÀÇ ÆÇ¸·ÀÌ ¾î¶² ¿øÀÎÀ¸·Î ¼Õ»óµÇ¾î ÆÇ¸·ÀÇ ±â´ÉÀÌ À¯ÁöµÉ ¼ö ¾øÀ» ¶§ ÀÌ ÆÇ¸·À» ¼ºÇüÇØ¼ ´Ù½Ã »ç¿ëÇϰųª(ÆÇ¸·¼ºÇü¼ú) ÀΰøÆÇ¸·À¸·Î ġȯ(ÆÇ¸·Ä¡È¯¼ú)ÇØ ÁÖ¾î¾ß ÇÑ´Ù. ÀΰøÆÇ¸·¿¡´Â Å©°Ô µÎ °¡Áö°¡ Àִµ¥ Çϳª´Â µÅÁö³ª ¼Ò µîÀÇ »ýüÁ¶Á÷À¸·Î ¸¸µç Á¶Á÷ÆÇ¸·ÀÌ°í ´Ù¸¥ Çϳª´Â ±Ý¼ÓÀçÁú·Î ¸¸µç ±â°èÆÇ¸·ÀÌ´Ù. ÀÌ µÎ ÆÇ¸·Àº ¼·Î Àå´ÜÁ¡ÀÌ Àִµ¥, Á¶Á÷ÆÇ¸·Àº ¼ö¸íÀÌ 10³â Á¤µµ·Î ªÀº ´ÜÁ¡ÀÌ ÀÖ´Â ¹Ý¸é¿¡ ÆÇ¸· ÁÖÀ§¿¡ Ç÷¾×ÀÀ°í°¡ Àû¾î Ç×ÀÀ°íÁ¦ º¹¿ëÀÌ ÇÊ¿ä ¾ø°í, ¼Õ»óÀÌ ¼¼È÷ ÀϾÙ. |
||
| FIA | fistula in ano; fluorescent immunoassay; focal immunoassay; Freund incomplete adjuvant |
|---|---|
| PVE | Prosthetic Valve Endocarditis |
| APRL | American Prosthetic Research Laboratory |
| PIE | postinfectious encephalomyelitis preimplantation embryo; prosthetic infectious endocarditis; pulmona... |
| PROM | passive range of motion; premature rupture of fetal membranes; prolonged rupture of fetal membranes;... |
| PVE | Prosthetic valve endocarditis |
|---|---|
| PHV | prosthetic heart valve |
| ARIS | Apoenzyme Reactivation Immunoassay System |
| EMIT | Enzyme Immunoassay |
| ELISA | Enzyme Linked Immunoassay |
| prosthetic | Artificial implant, as in an artificial organ or limb. (27 Sep 1997) |
|---|---|
| prosthetic dentistry | A dental specialty concerned with the restoration and maintenance of oral function by the replacement of missing teeth and structures by artificial devices or prostheses. (12 Dec 1998) |
| prosthetic group | A tightly bound nonpolypeptide structure required for the activity of an enzyme or other protein, for example the haem of haemoglobin. (18 Nov 1997) |
| prosthetic valves | Valves used to replace human valves. They are divided into mechanical and tissue valves. The tissue is divided into homografts and heterografts. There are many different types of prosthetic valves, including the Saint Jude valve, Hancock valve, Starr-Edwards valve, and Carpentier-Edwards valve. (05 Mar 2000) |
| microparticle enzyme immunoassay | A technique in which the solid-phase support consists of very small microparticles in liquid suspension. Specific reagent antibodies are covalently bound to the microparticles. Antigen, if present, is then "sandwiched" between bound antibodies and antigen-specific, enzyme-labelled antibodies. Antigen-antibody complexes are detected and quantitated by analysis of fluorescence from the enzyme-substrate interaction. Acronym: MEIA (05 Mar 2000) |
| solid phase immunoassay | Immunoassay in which the antigen or serum is bound to a solid surface, such as a microplate wall or the sides of a tube, the other reactants being free in solution. (05 Mar 2000) |
| double antibody immunoassay | A method of separating antibody-bound antigen (e.g., insulin) from free antigen by precipitating the former with antibody specific for immunoglobulin. Synonym: double antibody immunoassay, double antibody method. (05 Mar 2000) |
| immunoassay | <investigation> A process that measures and identifies a specific biological substance such as an antigen. (09 Oct 1997) |
| thin-layer immunoassay | A method for detection of antigen-antibody reactions, applicable to detection of either antigen or antibody, based on the fact that either reactant, when added to a polystyrene surface (such as a well in a polystyrene plate) is adsorbed as a thin layer and acts as an immunosorbent capable of binding with the second reactant. (05 Mar 2000) |
| enzyme immunoassay | The general term for an expanding technical arsenal of testing which allows a full range of quantitative analyses for both antigen and antibodies. These tests use colour-changed products of enzyme-substrate interaction (or inhibition) to measure the antigen-antibody reaction. Examples of EIA procedures (EMIT, ELISA, MAC, MEIA) follow. Acronym: EIA (05 Mar 2000) |
| enzyme-multiplied immunoassay technique | A type of immunoassay in which the ligand is labelled with an enzyme, and the enzyme-ligand-antibody complex is enzymatically inactive, allowing quantitation of unlabelled ligand. The test uses antibodies that react only with the particular drug for which the sample is being tested. The antibodies attach themselves to the drug if it is present in the sample. It is not designed to measure amounts of the drug present, only to detect its presence or absence. It is used predominantly, but not exclusively, for the detection of drugs of abuse in the urine. See: competitive binding assay, enzyme-linked immunosorbent assay. (05 Mar 2000) |
| fluorescence immunoassay | <technique> A sensitive technique which uses fluorescein, a fluorescent molecule, to measure the antigen or antibody concentration in a solution. (09 Oct 1997) |
| fluorescence polarisation immunoassay | A technique which takes advantage of the increased polarisation (non-random propagation of emission) of fluorescent light emissions when a fluorescent labelled antigen is bound by reagent antibody. The higher the concentration of unlabelled patient antigen present in the test mixture, the less bound fluorescent antigen is present and, consequently, the lower the polarisation of the fluorescent light emission. Standard calibration yields quantitative results. (05 Mar 2000) |
| fluorescence polarization immunoassay | Fluoroimmunoassay where detection of the hapten-antibody reaction is based on measurement of the increased polarization of fluorescence-labelled hapten when it is combined with antibody. The assay is very useful for the measurement of small haptenic antigens such as drugs at low concentrations. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|